Osteoblastic 11β-hydroxysteroid dehydrogenase type 1 activity increases with age and glucocorticoid exposure

被引:156
|
作者
Cooper, MS
Rabbitt, EH
Goddard, PE
Bartlett, WA
Hewison, M
Stewart, PM
机构
[1] Univ Birmingham, Queen Elizabeth Hosp, Div Med Sci, Birmingham B15 2TH, W Midlands, England
[2] Birmingham Heartlands & Solihull NHS Trust, Dept Clin Biochem & Immunol, Birmingham, W Midlands, England
关键词
11 beta-hydroxysteroid dehydrogenase; bone; osteoblasts; glucocorticoids; cortisol; osteoporosis; aging;
D O I
10.1359/jbmr.2002.17.6.979
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The risk of glucocorticoid-induced osteoporosis increases substantially with age but there is considerable individual variation. In recent studies we have shown that the effects of glucocorticoids on bone are dependent on autocrine actions of the enzyme 1113-hydroxysteroid dehydrogenase type 1 (11beta-HSD1); expression of 11beta-HSD1 in osteoblasts (OBs) facilitates local synthesis of active glucocorticoids with consequent effects on osteoblastic proliferation and differentiation. Using primary cultures of human OBs, we have now characterized the age-specific variation in osteoblastic 11beta-HSD1 and defined enzyme kinetics and regulation using natural and therapeutic glucocorticoids. 11beta-HSD1 reductase activity (cortisone to cortisol conversion) was recognized in all OB cultures and correlated positively with age (r = 0.58 with all cultures, p < 0.01, and n = 18; r = 0.87 with calcaneal-derived cultures, p < 0.001, and n = 14). Glucocorticoid treatment caused a time- and dose-dependent increase in 11beta-HSD1 activity over control (e.g., dexamethasone [DEX; 1 muM], 2.6-fold +/-0.5 (mean +/- SE),p < 0.001, and n = 16; cortisol (100 nM), 1.7-fold +/- 0.1, p < 0.05, and n = 14). Similar increases in 11beta-HSD1 mRNA expression were indicated using real-time quantitative reverse-transcription polymerase chain reaction (RT-PCR) analyses (3.5-fold with DEX, p < 0.01; 2.5-fold with cortisol, p < 0.05). The capacity of 11beta-HSD1 to metabolize the synthetic glucocorticoids prednisone and prednisolone was investigated in human OBs (hOBs) and fetal kidney-293 cells stably transfected with human 11beta-HSD1 cDNA. Transfected cells and hOBs were able to interconvert prednisone and prednisolone with reaction kinetics indistinguishable from those for cortisone and cortisol. To assess the in vivo availability of substrates for osteoblastic 11beta-HSD1, plasma cortisone and prednisone levels were measured in normal males before and after oral prednisolone (5 mg). The 9:00 a.m. serum cortisone levels were 110 +/- 5 nmol/liter and prednisone levels peaked at 78 +/- 23 nmol/liter 120 minutes after administration of prednisolone. Thus, therapeutic use of steroids increases substrate availability for 11beta-HSD1 in bone. These studies indicate that activation of glucocorticoids at an autocrine level within bone is likely to play an important role in the age-related decrease in bone formation and increased risk of glucocorticoid-induced osteoporosis.
引用
收藏
页码:979 / 986
页数:8
相关论文
共 50 条
  • [1] Inhibition of 11β-hydroxysteroid dehydrogenase type 1 activity in vivo limits glucocorticoid exposure to human adipose tissue and decreases lipolysis
    Tomlinson, Jeremy W.
    Sherlock, Mark
    Hughes, Beverley
    Hughes, Susan V.
    Kilvington, Fiona
    Bartlett, William
    Courtney, Rachel
    Rejto, Paul
    Carley, William
    Stewart, Paul M.
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (03): : 857 - 864
  • [2] 11β-hydroxysteroid dehydrogenase type 1 increases with age and photoexposure in human skin ex vivo
    Tiganescu, A.
    Walker, E. A.
    Mayes, A. E.
    Stewart, P. M.
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2011, 131 : S91 - S91
  • [3] The ratio of 11β-hydroxysteroid dehydrogenase 1/11β-hydroxysteroid dehydrogenase 2 predicts glucocorticoid response in nasal polyps
    Lijie Jiang
    Min Zhou
    Jie Deng
    Yueqi Sun
    Kejun Zuo
    Rui Zheng
    Jianbo Shi
    Yinyan Lai
    [J]. European Archives of Oto-Rhino-Laryngology, 2019, 276 : 131 - 137
  • [4] Evolution of 11β-hydroxysteroid dehydrogenase-type 1 and 11β-hydroxysteroid dehydrogenase-type 3
    Baker, Michael E.
    [J]. FEBS LETTERS, 2010, 584 (11) : 2279 - 2284
  • [5] Intravascular glucocorticoid metabolism by 11β-hydroxysteroid dehydrogenase type 1 following arterial injury
    Macdonald, J.
    Dover, A. R.
    Miller, E.
    Walker, B. R.
    Hadolke, P. W. F.
    [J]. HYPERTENSION, 2006, 48 (04) : 767 - 767
  • [6] Changing glucocorticoid action: 11β-Hydroxysteroid dehydrogenase type 1 in acute and chronic inflammation
    Chapman, Karen E.
    Coutinho, Agnes E.
    Zhang, Zhenguang
    Kipari, Tiina
    Savill, John S.
    Seckl, Jonathan R.
    [J]. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2013, 137 : 82 - 92
  • [7] 11β-hydroxysteroid dehydrogenase type 1 as a modulator of glucocorticoid action:: from metabolism to memory
    Seckl, JR
    Walker, BR
    [J]. TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2004, 15 (09): : 418 - 424
  • [8] 11β-hydroxysteroid dehydrogenase type 1:: A tissue-specific regulator of glucocorticoid response
    Tomlinson, JW
    Walker, EA
    Bujalska, IJ
    Draper, N
    Lavery, GG
    Cooper, MS
    Hewison, M
    Stewart, PM
    [J]. ENDOCRINE REVIEWS, 2004, 25 (05) : 831 - 866
  • [9] Is 11ß-hydroxysteroid dehydrogenase type 1 a good therapeutic target for blockade of glucocorticoid actions?
    Chrousos, GP
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (17) : 6329 - 6330
  • [10] Expression of 11β-hydroxysteroid dehydrogenase type 1 (11HSD1) and glucocorticoid synthesis in immune cells
    Ergang, P.
    Leden, P.
    Vagnerova, K.
    Vitackova, K.
    Miksik, I.
    Kment, M.
    Pacha, J.
    [J]. FEBS JOURNAL, 2007, 274 : 289 - 289